Search results for " Moda"

showing 10 items of 687 documents

Effectiveness of platinum wire microcoils for venous occlusion: A study on patients treated for venogenic impotence

1994

The purpose of this study was to determine the effectiveness of venous occlusions achieved by embolization with platinum microwire coils. Follow-up venographies in 19 patients, 1-20 months (average 8 months) after coil embolizations, were evaluated. Twenty-eight of 126 (22.2%) coil embolizations were found to be patent. Coils which had not formed or partially formed upon embolization had a patency/recanalization rate of 37.5% (12/32). Among coils which had formed nearly completely or completely only 16 of 95 (17%) showed venous patency. As coil embolization had been augmented by sclerotherapy in all patients, the effectiveness of long-term venous occlusion by platinum wire coils alone is pr…

Malemedicine.medical_specialtySurface Propertiesmedicine.medical_treatmentchemistry.chemical_elementThrombogenicityVeinsErectile DysfunctionSclerotherapymedicineSclerotherapyHumansRadiology Nuclear Medicine and imagingEmbolizationVascular PatencyPlatinumPeripheral Vascular DiseasesVascular diseasebusiness.industryVenous occlusionAngiographyVenogenic Impotencemedicine.diseaseCombined Modality TherapyEmbolization TherapeuticSurgerychemistryElectromagnetic coilCardiology and Cardiovascular MedicinePlatinumbusinessNuclear medicineFollow-Up StudiesPenisCardiovascular and Interventional Radiology
researchProduct

Is delayed facilitated percutaneous coronary intervention better than immediate in reperfused myocardial infarction? Six months follow up findings

2006

Background: There are several new strategies proposed to improve the outcome of patients with ST-elevation myocardial infarction (STEMI). One approach is the resurgent use of facilitated percutaneous coronary interventions (PCI). Until recently, deciding whether immediate PCI after combined treatment (facilitated PCI) is more appropriate than delayed PCI (short time) has not been investigated. The aim of this study, therefore, was to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI < 2 hr, and in patients initially successfully treated with pharmacological therapy and with delayed PCI (12–72 h). Methods: 451 reperfused STEMI patients, a…

Malemedicine.medical_specialtyTiclopidineTime Factorsmedicine.medical_treatmentMyocardial InfarctionFacilitated Percutaneous Coronary InterventionPlatelet Glycoprotein GPIIb-IIIa ComplexGIIb/IIIa inhibitorDelayed Percutaneous Coronary InterventionsInternal medicineAngioplastymedicineAbciximabAcute myocardial InfarctionHumanscardiovascular diseasesMyocardial infarctionAngioplasty Balloon CoronaryAgedbusiness.industryAnticoagulantsPercutaneous coronary interventionHematologyTirofibanMiddle AgedClopidogrelmedicine.diseaseCombined Modality TherapyClopidogrelsurgical procedures operativeTissue Plasminogen ActivatorConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinesstherapeuticsCombined therapyPlatelet Aggregation InhibitorsTIMIFollow-Up Studiesmedicine.drugJournal of Thrombosis and Thrombolysis
researchProduct

Effects of Myofascial Release in Nonspecific Chronic Low Back Pain: A Randomized Clinical Trial.

2017

Double-blind, randomized parallel sham-controlled trial with concealed allocation and intention-to treat analysis.To investigate the effects of an isolate myofascial release (MFR) protocol on pain, disability, and fear-avoidance beliefs in patients with chronic low back pain (CLBP).MFR is a form of manual medicine widely used by physiotherapists in the management of different musculoskeletal pathologies. Up to this moment, no previous studies have reported the effects of an isolated MFR treatment in patients with CLBP.Fifty-four participants, with nonspecific CLBP, were randomized to MFR group (n = 27) receiving four sessions of myofascial treatment, each lasting 40 minutes, and to control …

Malemedicine.medical_specialtyTreatment outcomeMEDLINElaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawSurveys and QuestionnairesMedicineHumansOrthopedics and Sports MedicineIn patient030212 general & internal medicinePhysical Therapy ModalitiesAgedbusiness.industryMiddle AgedMyofascial releaseChronic low back painTreatment OutcomePhysical therapyFemaleNeurology (clinical)Chronic PainbusinessLow Back Pain030217 neurology & neurosurgerySpine
researchProduct

Treatment of Severe Post-Prostatectomy Stress Urinary Incontinence Using Advance Sling

2010

Severe stress urinary incontinence (SUI) is usually treated by the implant of artificial sphincter positioned around bulbar urethra. AdVance sling is a functional, non-obstructive, anti-incontinence device that showed good results especially for mild and moderate SUI. We present our experience with AdVance sling in 7 patients with severe SUI unfit for artificial sphincter. Our results, after a follow-up of more than 6 months, showed a continence rate of 28% and an improvement rate of 43%, while 2 patients did not show any benefit. The success of AdVance sling depends on the integrity of urethral sphincter and can be applied also in selected cases for the treatment of severe post-prostatect…

Malemedicine.medical_specialtyUrinary Incontinence Stressmedicine.medical_treatmentUrologyUrinary incontinenceAdenocarcinomaDiabetes ComplicationsProsthesis ImplantationPostoperative ComplicationsHumansMedicinePost prostatectomyAgedRetrospective StudiesProstatectomybusiness.industryProstatectomyUrethral sphincterProstatic NeoplasmsRetrospective cohort studyProstheses and ImplantsGeneral MedicineMiddle AgedAdvance slingCombined Modality TherapyTreatment OutcomeChemotherapy AdjuvantImprovement rateHypertensionRadiotherapy AdjuvantImplantmedicine.symptombusinessUrologia Journal
researchProduct

Extent of Surgery in Rhabdomyosarcoma of Urogenital Structures

1989

After high inguinal semicastration in group-1 paratesticular rhabdomyosarcoma (RMS), the patient having undergone chemotherapy can be followed closely by CT scanning without retroperitoneal lymphadenectomy. In contrast, retroperitoneal RMS should be operated on as radically as possible after downstaging the tumor mass. In RMS of the female genitalia locally limited organ-preserving surgery is the method of choice. The prognosis is excellent with adjuvant chemotherapy. Only 20% of all bladder RMS arise from the bladder dome or the movable part of the bladder, where primary partial resection including a safety margin of 3 cm of healthy tissue is possible. The majority, however, arising from t…

Malemedicine.medical_specialtyUrologymedicine.medical_treatmentProstatic urethraAntineoplastic Combined Chemotherapy ProtocolsRhabdomyosarcomamedicineHumansChildRhabdomyosarcomaUpper urinary tractGenitourinary systembusiness.industryUrinary diversionRadiotherapy DosagePrognosismedicine.diseaseCombined Modality TherapySurgeryNeck of urinary bladdermedicine.anatomical_structureFemalebusinessContinent Urinary DiversionUrogenital NeoplasmsChemoradiotherapyFollow-Up StudiesEuropean Urology
researchProduct

Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer.

2005

OBJECTIVES To report the long-term follow-up of patients with locally advanced bladder cancer treated with either adjuvant combined chemotherapy with methotrexate, vinblastine, doxorubicin/epirubicin, and cisplatin (MVAC/MVEC) or no additional treatment after radical cystectomy, to examine various survival endpoints and factors associated with long-term survival. PATIENTS AND METHODS Between May 1987 and December 1990, 49 patients undergoing radical cystectomy for locally advanced bladder cancer were randomized to observation only or adjuvant systemic chemotherapy with three cycles of MVAC/MVEC (methotrexate 30 mg/m2 on day 1, 15 and 22; vinblastine 3 mg/m2 on day 2, 15 and 22; doxorubicin …

Malemedicine.medical_specialtyUrologymedicine.medical_treatmentUrologyCystectomyVinblastineDisease-Free SurvivalCystectomyAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansAgedEpirubicinChemotherapyBladder cancerbusiness.industryHazard ratioCombination chemotherapyMiddle Agedmedicine.diseaseInterim analysisCombined Modality TherapyVinblastineSurgeryMethotrexateTreatment OutcomeUrinary Bladder NeoplasmsChemotherapy AdjuvantDoxorubicinLymphatic MetastasisFemaleCisplatinNeoplasm Recurrence Localbusinessmedicine.drugEpirubicinFollow-Up StudiesBJU international
researchProduct

Primary Radical Prostatectomy or Ablative Radiotherapy as Protective Factors for Patients With mCRPC Treated With Radium-223 Dichloride: An Italian M…

2020

Abstract Background We investigated, in a real-life setting, the prognostic relevance of previous primary treatment (radical prostatectomy [RP] or external beam radiotherapy [EBRT]) on overall survival for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (223Ra). Materials and Methods In the present multicenter retrospective study, we enrolled 275 consecutive patients. The demographic and clinical data and mCRPC characteristics were recorded and evaluated at baseline and at the end of treatment or progression. 223Ra was administered according to the current label authorization until disease progression or unacceptable toxicity. We divided the who…

Malemedicine.medical_specialtyUrologymedicine.medical_treatmentoverall survivalBrachytherapy030232 urology & nephrologyUrology223-ra03 medical and health sciencesProstate cancer0302 clinical medicineAblative casemedicineHumansExternal beam radiotherapyradiotherapyAgedRetrospective StudiesAged 80 and overProstatectomyRadioisotopesbusiness.industryProstatectomyRetrospective cohort studymCRPCMiddle AgedProtective Factorsmedicine.diseasePrognosisCombined Modality TherapyRadiation therapySurvival RateProstatic Neoplasms Castration-ResistantOncologyMulticenter study223-ra; mCRPC; prostatectomy; radiotherapy; overall survivalItaly030220 oncology & carcinogenesisCohortDisease ProgressionbusinessSettore SECS-S/01Follow-Up StudiesRadium
researchProduct

Rhabdomyosarcoma of the bladder, prostate or vagina: the role of surgery

2003

Rhabdomyosarcoma of pelvic organs is not common enough for many people to develop large series. However, the authors from Mainz retrospectively analysed 107 children with this condition, and suggest that primary chemotherapy followed by radical surgery yields excellent cure rates. OBJECTIVE To retrospectively analyse the outcome of children with rhabdomyosarcoma (RMS) of the bladder, prostate or vagina who were treated with chemotherapy, with or without radical surgery or additional radiotherapy, at our institution since 1968. PATIENTS AND METHODS From a total of 107 children with RMS seen between 1968 and December 2001, 22 (mean age 5.9, range 0.5–18) had RMS of bladder/prostate or vagina.…

Malemedicine.medical_specialtyVaginal NeoplasmsAdolescentUrologymedicine.medical_treatmentUrologyUrinary DiversionCystectomyAntineoplastic Combined Chemotherapy ProtocolsRhabdomyosarcomamedicineHumansRadical surgeryChildRhabdomyosarcomaRetrospective StudiesProstatectomyIfosfamideUrinary bladderbusiness.industryUrinary diversionInfantProstatic Neoplasmsmedicine.diseaseCombined Modality TherapySurgeryTreatment Outcomemedicine.anatomical_structureUrinary Bladder NeoplasmsBladder augmentationChild PreschoolFemalePouchbusinessContinent Urinary DiversionFollow-Up Studiesmedicine.drugBJU International
researchProduct

Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend?

2007

The aim of the present study was to evaluate the effects of a normal-sodium (120 mmol sodium) diet compared with a low-sodium diet (80 mmol sodium) on readmissions for CHF (congestive heart failure) during 180 days of follow-up in compensated patients with CHF. A total of 232 compensated CHF patients (88 female and 144 male; New York Heart Association class II–IV; 55–83 years of age, ejection fraction &amp;lt;35% and serum creatinine &amp;lt;2 mg/dl) were randomized into two groups: group 1 contained 118 patients (45 females and 73 males) receiving a normal-sodium diet plus oral furosemide [250–500 mg, b.i.d. (twice a day)]; and group 2 contained 114 patients (43 females and 71 males) recei…

Malemedicine.medical_specialtyfood.dietLow sodium dietPlasma renin activityGastroenterologyPatient Readmissionchemistry.chemical_compoundfoodFurosemideInternal medicineNatriuretic Peptide BrainReninmedicineHumansDiureticsAldosteroneAgedAged 80 and overHeart FailureEjection fractionAldosteronebusiness.industryFurosemideSodium DietaryGeneral MedicineDiet Sodium-RestrictedMiddle Agedmedicine.diseaseBrain natriuretic peptideCombined Modality TherapySurvival AnalysisEndocrinologyTreatment OutcomechemistryHeart failureFemalebusinessmedicine.drugLow sodiumFollow-Up StudiesClinical science (London, England : 1979)
researchProduct

Fibrosarcoma in pediatric patients: Results of the Italian Cooperative Group Studies (1979-1995)

2001

Background and Objectives Fibrosarcoma is a rare soft tissue sarcoma (STS) that has two peaks of incidence in pediatric patients: one in infants and young childern (infantile fibrosarcoma), another in older children (“adult type” fibrosarcoma). The purpose of this study was to describe the clinical features and the treatment results in patients affected by fibrosarcoma enrolled in two consecutive studies run by the STS-Italian Cooperative Group (ICG) between 1979 and 1995. Patients and Methods Twenty-five evaluable patients were grouped according the intergroup rhabdomyosarcoma staging (IRS) system: 12 Gr I, 5 Gr II, 8 Gr III. The cut-off point between the two forms was considered the age o…

Malemedicine.medical_specialtyinfantile fibrosarcomaAdolescentmedicine.medical_treatmentSoft Tissue NeoplasmsSettore MED/38 - Pediatria Generale E SpecialisticamedicineHumansFibrosarcomaRhabdomyosarcomaChildSurvival analysisfibrosarcoma; infantile fibrosarcoma; soft tissue sarcomabusiness.industrySoft tissue sarcomaSettore MED/20 - Chirurgia Pediatrica E InfantileAge FactorsInfantRadiotherapy DosageSarcomaGeneral Medicinemedicine.diseaseCombined Modality TherapySurvival AnalysisSurgeryRadiation therapyTreatment OutcomeOncologyChild Preschoolsoft tissue sarcomaSurgeryFemalefibrosarcomaSarcomaInfantile FibrosarcomabusinessProgressive disease
researchProduct